FDA Complete Response Letters: How to Verify a Resubmission Timeline

What does a CRL establish?

A Complete Response Letter (CRL) means FDA will not approve an application in its current form. It identifies deficiencies; it does not establish a future approval date or the applicant's eventual success. Start with the letter and the application it addresses, rather than treating a company headline as the complete regulatory record. FDA's CRL database explanation

For an investor building a timeline, the useful question is: what evidence shows that the applicant has completed the work, submitted a response, and received a new review goal date? A CRL announcement alone leaves those later steps unconfirmed.

Keep remediation and review on separate clocks

The first interval is the applicant's work after the CRL: resolving the identified deficiencies and assembling its response. The second is FDA's review of a resubmission. A forecast for the first interval cannot be replaced by a standard review duration.

21 CFR 314.110 provides for a new two-month review cycle for an application or efficacy supplement classified by FDA as Class 1, or six months for Class 2, beginning when FDA receives the resubmission. Those durations do not start on the CRL announcement date. The regulation also allows a CRL to precede required inspections or labeling review when the submitted data are inadequate. Absence of an objection in a company summary therefore cannot establish that every other review area is clear.

What do Class 1 and Class 2 tell you?

The PDUFA VII goals for fiscal years 2023–2027 target action on 90% of Class 1 resubmitted original applications and efficacy supplements within two months of receipt, and Class 2 within six months. These are review-performance goals, not approval probabilities or guarantees for an individual application. A major amendment during review may extend the goal date by three months.

Classification depends on the response package. PDUFA's definitions limit Class 1 to specified items, such as labeling and certain minor updates or clarifications; other items fall into Class 2. Do not infer the class solely from “manufacturing-only” or “no new clinical trial required.” For context, CBER's resubmission procedure lists a new manufacturing facility or a needed follow-up assessment or inspection among Class 2 items. Check the applicable program and FDA's actual designation; the Class 1/2 framework is not universal across every application type.

Build a dated evidence ledger

Use one row for each event, with the original source and its disclosure date:

Event	Evidence to capture	What remains unconfirmed
CRL issued	Letter, application identity and deficiencies	Remediation completion and future approval
Response planned	Applicant's dated disclosure and dependencies	Whether submission has occurred
Response submitted	Actual submission disclosure and scope	FDA's assessment and confirmed goal date
FDA acknowledges response	Receipt, classification and goal-date communication	Whether deficiencies are adequately resolved
Subsequent FDA action	Original approval or other action record	Nothing should be inferred from an earlier forecast

CBER distinguishes a response addressing each issue from a response that adequately resolves each issue. Its procedure says an incomplete response does not restart review until a complete response is received; adequacy is evaluated during review. Acknowledgement and approval are separate milestones. This is a CBER procedure, so identify the reviewing center before applying its operational details. SOPP 8405.1, definitions and policy

Read the letter, then test the valuation assumption

FDA publishes redacted CRLs for approved and unapproved NDA/BLA applications. Confidential material may be removed and updates are infrequent. A missing public letter does not establish that no CRL exists, and redacted passages remain UNKNOWN. Compare available FDA correspondence with the applicant's dated disclosure; preserve disagreements rather than guessing omitted deficiencies. openFDA CRL documentation

For company research, record the confirmed milestone, unresolved work and funding dependencies. Keep management's target separate from an actual submission and FDA-confirmed goal date. Use the research entry below to choose a company and audit timing, costs and other pipeline valuation assumptions against cited evidence. Missing inputs remain unknown; the article supplies a framework, not a current company forecast or a price target. If timing affects liquidity, review the latest filings using the cash-runway framework.